Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
Large-scale trials see decrease in dengue infections following release of Wolbachia-infected mosquitos
A team of researchers presented the first large-scale evidence that releasing Wolbachia-infected mosquitoes reduced dengue infections by >70% in high-risk populations.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
New research has assessed a genetically engineered fungus for the control of malaria mosquitoes in the first semi-field trial, demonstrating that populations were reduced by more than 99%.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Madariaga virus has been identified as the cause of acute febrile illness in eight children in Haiti between 2015 and 2016 – the first time it has been discovered in the country.
Take a look behind the scenes of a recent Future Virology paper as we ask author Prof. Mohamed El Zowalaty about the challenges facing the field of arboviruses, from climate change to urbanization, both in South Africa and across the world.
With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.